CELGENE CORP /DE/·4

Dec 24, 4:04 PM ET

CELGENE CORP /DE/ 4

4 · CELGENE CORP /DE/ · Filed Dec 24, 2013

Insider Transaction Report

Form 4
Period: 2013-12-23
STEIN LAWRENCE V
See Remarks
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2013-12-2312,06241,271 total
    Exercise: $78.66Exp: 2022-12-03Common Stock (12,062 underlying)
  • Exercise/Conversion

    Common Stock

    2013-12-23$78.66/sh+12,062$948,79712,112 total
  • Sale

    Common Stock

    2013-12-23$168.19/sh12,062$2,028,68550 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    55
Footnotes (3)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $168.10 to $168.43, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to this Form 4.
  • [F2]The option was fully exercisable.
  • [F3]The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013).

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION